14.	CIRM Grant

On April 30, 2019, the Company announced that CIRM awarded Rocket up to a $6.5 million CLIN2 grant award to support the clinical development of gene therapy for LAD-I. Proceeds from the grant will help fund clinical trial costs as well as manufactured drug product for Phase I/II patients enrolled at the U.S. clinical site, University of California, Los Angeles (“UCLA”) Mattel Children’s Hospital, led by principal investigator Donald Kohn, M.D., UCLA Professor of Microbiology, Immunology and Molecular Genetics, Pediatrics (Hematology/Oncology), Molecular and Medical Pharmacology and member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA. The CIRM grant receipts were treated as an offset against R&D expenses as reimbursable expenses are incurred. As of September 30, 2019, the Company recorded a receivable and reduction of R&D expenses of $0.4 million for the reimbursable expenses incurred for the three months ended September 30, 2019.